Law firm accuses of securities fraud under Section 10(b) and Rule 10b-5

In a recent securities class action lawsuit against Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Levi & Korsinsky, LLP is urging shareholders who purchased INO securities between October 10, 2023, and December 26, 2025, to review their options if they lost money on their investment during this period. The legal framework protecting investors, namely Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, prohibits the dissemination of false or misleading material information about a company’s business, operations, and prospects.

The complaint filed in the United States District Court for the Eastern District of Pennsylvania alleges that Inovio Pharmaceuticals and its executives failed to disclose critical information regarding the manufacturing deficiencies of the CELLECTRA device, the delay in submitting its BLA by the projected timeline, the lack of sufficient information to warrant accelerated approval eligibility, and the overstated regulatory and commercial prospects of their product. These allegations are a violation of Section 10(b) and Rule 10b-5, prompting the lawsuit against the company.

Moreover, the complaint also asserts that individual defendants within the company, under Section 20(a) of the Exchange Act, are control persons who should be held accountable for their roles in the alleged securities violations. This legal protection for investors ensures that those in senior positions and with the ability to control public disclosures are held responsible when misleading or false information is conveyed to investors.

“The PSLRA provides important protections for investors harmed by alleged securities violations,” said Joseph E. Levi, Esq., emphasizing the severity of the issues raised in the complaint regarding executives’ knowledge and the contents of SEC filings. Levi & Korsinsky, LLP, a nationally recognized firm specializing in shareholder rights litigation, has been ranked in ISS Securities Class Action Services’ Top 50 Report for seven consecutive years and has garnered hundreds of millions of dollars in recoveries for investors nationwide.

With the deadline for filing motions for lead plaintiff set for April 7, 2026, investors affected by the alleged deceptive practices of Inovio Pharmaceuticals are encouraged to engage with legal counsel to explore their options and potential for compensation. As the lawsuit progresses, more details will be revealed regarding the company’s actions and the impact on shareholders.